Furthermore, Hoh et al. demonstrated improved anti-tumor effects against hepatocellular carcinoma and hepatoblastoma cells with MT110, an epithelial cell adhesion molecule EpCAM/CD3 bispecific T-cell engager antibody, compared to the anti-EpCAM antibody adecatumumab (222). Here, EPCAM is linked to neoplasm.